Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hansa Biopharma AB ( (SE:HNSA) ) has provided an update.
Hansa Biopharma has secured a USD 30 million unsecured convertible senior notes financing from funds managed by Athyrium Capital Management, extending its cash runway into mid-2027. The funding is intended to support a robust planned U.S. launch of imlifidase for highly sensitized kidney transplant candidates, reinforcing the company’s commercial build-out in a critical niche of the transplant market.
The notes, maturing in 2031 with a 3% fixed interest rate, are convertible at a roughly 25% premium to Hansa’s recent share price, with an option for net share settlement to limit dilution. Hansa has issued 4,190,805 treasury-held warrants to cover potential conversions, and the structure includes a minimum 1.6x return for investors, underscoring Athyrium’s confidence in imlifidase’s market potential while carefully balancing shareholder dilution.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK29.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on novel immunomodulatory therapies for acute and complex immune disorders. Leveraging its proprietary IgG-cleaving enzyme technology, the company targets serious unmet needs in transplantation, gene therapy and autoimmune diseases, with flagship asset imlifidase and next-generation candidate HNSA-5487.
Average Trading Volume: 415,614
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK2.97B
See more data about HNSA stock on TipRanks’ Stock Analysis page.